about
HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groupsLibman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution.The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview SurveySuicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey.Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.Validation of new biomarkers in systemic autoimmune diseasesJoint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, EuropeRenal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging.Emerging Therapies in Antiphospholipid Syndrome.Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases.Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?Reiter's syndrome during intravesical BCG therapy for bladder carcinoma.Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report.Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance.Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked.Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study.Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016.Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus.Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015.MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathiesThe comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis
P50
Q28142194-4235ACC4-D9DA-4D0D-AA1E-F1BDACED23ADQ33375735-033B16EA-8B48-4901-A90D-8666C9BED39DQ33420116-587B3EFA-12EA-4795-B610-93C96A905169Q33709078-093930B0-72D4-47FC-8A74-5044F8B7BA4FQ33931907-2CFEBCF4-E079-425B-AFD3-69D704AFFC59Q35893859-BBA411D7-62B3-41EC-B53F-8FC9AAD8367AQ36231859-05704D0C-DB24-400B-BF8E-402B2C9A579EQ36302245-67C6D637-8288-4C5E-B656-D594CC97A563Q37306365-9DD71D55-C501-4195-B97F-0D646A160A3DQ37339048-75368145-57A5-4042-BB92-60CB61CC9168Q37352584-2B88280F-2BD1-43A8-AB5A-E2DF3EA4E62AQ38159868-1222370F-CA3E-4C6F-8056-10518F23609DQ38280730-27991FEF-B48F-4487-8DF9-709EDF7CC17AQ38652145-D8E5F0FE-2E28-4FB6-96B1-FE7A86F20586Q38782057-6CB008BB-10EE-40F4-AB10-C12BEAD527D3Q38930294-71C138C5-3D3C-402B-AAC0-E3D02CFBA8D6Q40341391-532F8783-66E9-4FF2-AAEC-3DE7D3DC549EQ40436057-6F53E585-CA7B-4DB1-A284-BBEC92CFA47CQ40472247-8EF99576-C34E-4C57-98AC-C513D1F1AE51Q40513776-406D8978-1F87-4E6A-B1D8-C1E0C7A9E678Q41444197-D110D0C1-1B18-4B15-9C9E-A09AD446C040Q41649482-777FD5A1-B6C0-4A24-9170-8017F13257CAQ41939439-31075294-D6E5-4C7E-8CDB-C70D39E50575Q44390798-5045C378-2DDE-4E2C-8D3D-B2DC8C05B250Q44412972-391420FC-62E6-4D27-A50F-6D5F820C6876Q45034886-ABE54E66-8EC9-45EC-BA6A-18C134CFA4D6Q45054462-E0EAE562-EE80-4C72-B43C-75903386A830Q46300288-9542BE95-F88A-46E2-A6CF-26B07DC2C146Q47680027-12D79EEE-6093-43FA-8823-101728AF025FQ47732038-6B6D4E00-EC6E-4097-9FBE-3EEC8F0A2640Q47768575-1FA6FE34-13E9-4456-9EA6-706B194F1806Q47873619-07A19613-B669-4FF4-BDF0-7B6422B5F2C1Q47915281-EED729D0-81DB-4205-BE2E-17BFDD5EEE6EQ49914732-2D68273B-AED4-4E33-8726-13C8B8137D23Q50891276-3FD5465B-8CD4-4A5A-9EC7-E052782F2CFDQ51563684-48329021-E3DF-40E8-9CFD-F7BBD17E2D43Q51738271-F4817D37-F7D2-4C8D-9C79-CBC6BB942998Q55177568-6FCA8099-CB8B-48AA-A80C-4D1AB95FCC42Q57167489-0206D6B8-150A-4F1C-A4CF-FF23A734449FQ64041096-36408CEE-2900-45B4-922F-5590D6DB5992
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria G Tektonidou
@ast
Maria G Tektonidou
@en
Maria G Tektonidou
@es
Maria G Tektonidou
@nl
type
label
Maria G Tektonidou
@ast
Maria G Tektonidou
@en
Maria G Tektonidou
@es
Maria G Tektonidou
@nl
prefLabel
Maria G Tektonidou
@ast
Maria G Tektonidou
@en
Maria G Tektonidou
@es
Maria G Tektonidou
@nl
P106
P1153
57194133895
P21
P31
P496
0000-0003-2238-0975